Startups set off new wave of mRNA therapeutics
Elie Dolgin • September 2, 2021
After the vaccine triumphs of Pfizer/BioNTech and Moderna, a raft of startups is developing mRNA, circular RNA and self-amplifying RNA therapeutics.
A cadre of new startups are building next-generation RNA platform technologies designed to solve some of the unique challenges associated with using conventional mRNA tools as therapeutics.
Read more at Nature Biotechnology.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.